Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Eribulin in HER2 Negative Metastatic BrCa

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute Identifier:
First received: April 3, 2013
Last updated: February 6, 2017
Last verified: February 2017

April 3, 2013
February 6, 2017
June 2013
June 2017   (Final data collection date for primary outcome measure)
Evaluation of Anti-Tumor Activity [ Time Frame: 2 years ]
To evaluate the antitumor activity of first-line treatment with single-agent eribulin mesylate in subjects with locally recurrent or metastatic HER2-negative breast cancer by determining overall response rate (ORR) (RECIST v1.1) ORR will be estimated separately for the HR+/HER2-and the TNBC monotherapy cohorts.
Same as current
Complete list of historical versions of study NCT01827787 on Archive Site
  • Progression-Free Survival [ Time Frame: 2 years ]
    Progression Free Survival
  • Time to First Response [ Time Frame: 2 years ]
    Time to First Response
  • Duration of Response [ Time Frame: 2 years ]
    Duration of Response
  • Time to First Response and Duration of Response [ Time Frame: 2 years ]
    Time to first response and duration of response
  • Describe the Adverse Event Profile of Eribulin [ Time Frame: 2 years ]
    To describe the adverse event (AE) profile of eribulin, according to provider-rated CTCAE v4.0
  • Describe QOL at Baseline and Over Time [ Time Frame: 2 years ]
    To describe QOL at baseline and over time using the Functional Assessment of Cancer Therapy-Breast (FACT-B)
  • Describe Impact of Neurotoxicity on QOL [ Time Frame: 2 years ]
    To describe the impact of neurotoxicity on QOL at baseline and over time using the FACT-Neurotoxicity Subscale (FACT-Ntx)
  • Describe Profile of Patient-Reported Symptomatic Toxicities [ Time Frame: 2 years ]
    To describe the profile of patient-reported symptomatic toxicities experienced by patients receiving treatment with eribulin using the Patient Reported Outcome (PRO) Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
  • Compare FACT-B, FACT-Ntx and PRO-CTCAE Toxicity Data with Provider Reported CTCAE Toxicity [ Time Frame: 2 years ]
    To compare FACT-B, FACT-Ntx and PRO-CTCAE toxicity data with provider-reported CTCAE toxicity to determine degree of concordance or divergence for each class of toxicity
Same as current
Not Provided
Not Provided
Eribulin in HER2 Negative Metastatic BrCa
A Phase 2 Study of Eribulin in Patients With HER2-Negative, Metastatic Breast Cancer: Evaluation of Efficacy, Toxicity and Patient-Reported Outcomes

This research study is a phase II clinical trial. Phase II clinical trials test the effectiveness of a drug to learn whether the drug works in treating a specific cancer.

Eribulin is a chemotherapy approved by the US FDA in November of 2010 to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens. It works by interfering with cancer cell division, growth and spread.

In this research study, the investigators are looking to see how well Eribulin helps participants with metastatic breast cancer as a first-line or second-line chemotherapy treatment. The investigators also would like to learn about the side-effects that participants experience with this medication, in particular, neuropathy.

Neuropathy is a condition in which the nerves are affected, leading to numbness or tingling of the fingers and toes. The investigators would like to study the effect Eribulin has on the nerves through regular questionnaires that ask about any nerve-related symptoms. The investigators also plan to send blood samples to determine if gene markers may indicate increased sensitivity to the nerve effects of Eribulin.

If you are willing to participate in this study you will be asked to undergo some screening tests and procedures to confirm your eligibility. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated. The screening tests and procedures will include: a medical history, a physical examination and vital signs, performance status, an assessment of your tumor, routine blood tests, pregnancy test and an electrocardiogram. If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in this research.

If you take part in this research study, you will be given Eribulin by intravenous infusion (by vein). The time to complete a single treatment is 60 minutes. You will receive Eribulin on Day 1 and Day 8 of each cycle. In the third week (Day 15) you will not receive any study medication. Each complete treatment cycle lasts 3 weeks.

During all cycles you will have a physical exam and you will be asked questions about your general health and specific questions about any problems that you might be having and any medications you may be taking.

At the beginning of cycles 1,2,3 and every other subsequent cycle, you will be asked to complete three online questionnaires using a wireless tablet computer provided in the clinic where you are being seen. This is a well established method of administering electronic questionnaires. No data will be stored on these computers. The data will be transmitted to servers where the data will be securely stored. Your data will be submitted using a special identification number. You will be given a username and a password. You will be given detailed instructions on how to use the computer and how to enter the data. If the wireless tablet computer is not working, paper forms will be provided. It will take about 15-30 minutes to complete. Some questions you will be asked to answer may make you feel uncomfortable. You may choose not to answer any questions that make you feel uncomfortable.

We will assess your tumor by the appropriate imaging modality (e.g., CT scan or MRI) every 9 weeks.

About 4 tablespoons of blood will be drawn to measure blood counts, organ function, and for other safety reasons. Blood tests will be done on Day 1 and Day 8 of every treatment cycle (every three weeks). One additional tube of blood (about 1 teaspoon) will be collected at Day 1 to be used to better understand the nerve toxicities of chemotherapy and to be used for future research on breast cancer.

You will have a follow-up visit three weeks after stopping study treatment. During that visit, you will have a physical exam, as well as an assessment of any side effects and current medications. If you continue to have on-going side effects related to your study treatment, we will continue to follow you until this side effect resolves. About 4 tablespoons of blood will be drawn to measure blood counts and organ function. If you stop therapy because of a side effect but your cancer is under control, we will continue to follow you with scans every 9 weeks until cancer growth is observed.

Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Breast Cancer
Drug: Eribulin
Intravenously on Day 1 and 8 of each cycle
Other Names:
  • E7389
  • Halaven
  • ER-086526
  • NSC-707389
  • Experimental: Hormone Receptor Positive
    Eribulin Monotherapy
    Intervention: Drug: Eribulin
  • Experimental: Triple Negative Breast Cancer
    Eribulin Monotherapy
    Intervention: Drug: Eribulin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
June 2017
June 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically proven invasive breast cancer, locally recurrent or metastatic, with at least one measureable lesion according to RECIST v1.1
  • Hormone receptor positive or hormone receptor negative HER2-negative disease
  • Up to one prior line of chemotherapy for advanced disease is allowed (discontinued at least 14 days prior to initiation of protocol therapy)
  • Prior bevacizumab in the neo/adjuvant or metastatic setting is acceptable
  • No limit on prior lines of endocrine therapy, but must be discontinued at least 7 days prior to initiation of protocol therapy
  • Must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapy
  • Must have recovered from reversible effects of prior therapies to no more than grade 1 toxicity, with the exception of alopecia
  • Agree to use adequate contraception for the duration of study participation

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Prior treatment with eribulin
  • Prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer unless diagnosed and definitively treated at least 3 years before enrollment in this study
  • Clinically significant cardiovascular impairment
  • Active brain metastases or unevaluated neurologic symptoms suggestive of brain metastases
  • Pulmonary dysfunction requiring the use of oxygen
  • Prior organ allograft requiring immunosuppression
  • HIV positive on combination antiretroviral therapy
  • Pre-existing grade 3 or 4 neuropathy
  • Hypersensitivity to halichondrin B or halichondrin B chemical derivative
  • Uncontrolled intercurrent illness
  • Inability to read in English
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Not Provided
Principal Investigator: Erica Mayer, MD, MPH Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP